rabbit polyclonal anti-c-rel cat Search Results


rabbit anti c rel  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc rabbit anti c rel
Rabbit Anti C Rel, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti-c-rel+cat/c-Rel+Rabbit+mAb/pmc10374607-10-0-3
Average 93 stars, based on 1 article reviews
rabbit anti c rel - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
6955 rrid ab 670194  (Santa Cruz Biotechnology)
95
Santa Cruz Biotechnology 6955 rrid ab 670194
KEY RESOURCES TABLE
6955 Rrid Ab 670194, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti-c-rel+cat/c-Rel+Antibody/pmc08968458-16-8-4
Average 95 stars, based on 1 article reviews
6955 rrid ab 670194 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
c rel  (Cell Signaling Technology Inc)
94
Cell Signaling Technology Inc c rel
KEY RESOURCES TABLE
C Rel, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti-c-rel+cat/c-Rel+Antibody/pmc11004450-89-25-26
Average 94 stars, based on 1 article reviews
c rel - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
anticreb antibody  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc anticreb antibody
KEY RESOURCES TABLE
Anticreb Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti-c-rel+cat/CREB+Rabbit+mAb/pm37222520-126-11-13
Average 96 stars, based on 1 article reviews
anticreb antibody - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
anti nfκb1 p105 p50  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc anti nfκb1 p105 p50
a , b Hallmark pathway of TNFA_NFKB ( a ) and KRAS ( b ) signaling AUC score cluster distributions. c , d Violin plots of the AUC score in TNFA_NFKB ( c ) and KRAS ( d ) signaling in KCs. e – g IB analysis of the indicated proteins of NF-κB and MAPK signaling pathway in HaCaT after treatment with LZTR1 sgRNA ( e ), primary mouse KC ( f ), and mouse epidermis ( g ). h – n MFI level of membrane HLA-ABC or mRNA level of HLA-A, HLA-B in Ctrl and LZTR1 KO HaCaT treated with 5 μM NF-κB inhibitor QNZ ( h – j ), si <t>NFKB1</t> ( k , l ) or overexpressed (oe)- NFKB1 ( m , n ). veh, vehicle ( n = 2–4). o qPCR of H2-D1 and H2-K1 mRNA expression in KCs from mice treated with si Nfkb1 and IFNγ ( n = 4). p , q Schematic diagram of promoter site construction and results for dual luciferase assay of HLA-A ( p ) and HLA-B ( q ) with si NFKB1 or oe- NFKB1 ( n = 3). r Relative enrichment fold of HLA-A and HLA-B promoter sequence immunoprecipitated with NF-κB1 in HaCaT analyzed by qPCR ( n = 3). s NF-κB1 predictive binding site on HLA-A and HLA-B promoter. t Schematic diagram of NF-κB1-binding deficiency promoter construction. u – x Quantification of luciferase activity level of HLA-A and HLA-B in WT or mutant promoter combined with si NFKB1 ( u , v ) and LZTR1 KO ( w , x ) ( n = 3). y Schematic mechanism diagram of LZTR1 regulating MHC-I. ns: not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 by Wilcoxon rank test ( c ), one-way ANOVA ( k ) and two-way ANOVA ( i , j , l , n – r , u – x ). Data are shown as mean ± SEM.
Anti Nfκb1 P105 P50, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti-c-rel+cat/NF-kappaB1+p105%2Fp50+Rabbit+mAb/pmc12572372-330-43-47
Average 96 stars, based on 1 article reviews
anti nfκb1 p105 p50 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
spcas9 2nls nuclease  (Synthego Inc)
86
Synthego Inc spcas9 2nls nuclease
a , b Hallmark pathway of TNFA_NFKB ( a ) and KRAS ( b ) signaling AUC score cluster distributions. c , d Violin plots of the AUC score in TNFA_NFKB ( c ) and KRAS ( d ) signaling in KCs. e – g IB analysis of the indicated proteins of NF-κB and MAPK signaling pathway in HaCaT after treatment with LZTR1 sgRNA ( e ), primary mouse KC ( f ), and mouse epidermis ( g ). h – n MFI level of membrane HLA-ABC or mRNA level of HLA-A, HLA-B in Ctrl and LZTR1 KO HaCaT treated with 5 μM NF-κB inhibitor QNZ ( h – j ), si <t>NFKB1</t> ( k , l ) or overexpressed (oe)- NFKB1 ( m , n ). veh, vehicle ( n = 2–4). o qPCR of H2-D1 and H2-K1 mRNA expression in KCs from mice treated with si Nfkb1 and IFNγ ( n = 4). p , q Schematic diagram of promoter site construction and results for dual luciferase assay of HLA-A ( p ) and HLA-B ( q ) with si NFKB1 or oe- NFKB1 ( n = 3). r Relative enrichment fold of HLA-A and HLA-B promoter sequence immunoprecipitated with NF-κB1 in HaCaT analyzed by qPCR ( n = 3). s NF-κB1 predictive binding site on HLA-A and HLA-B promoter. t Schematic diagram of NF-κB1-binding deficiency promoter construction. u – x Quantification of luciferase activity level of HLA-A and HLA-B in WT or mutant promoter combined with si NFKB1 ( u , v ) and LZTR1 KO ( w , x ) ( n = 3). y Schematic mechanism diagram of LZTR1 regulating MHC-I. ns: not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 by Wilcoxon rank test ( c ), one-way ANOVA ( k ) and two-way ANOVA ( i , j , l , n – r , u – x ). Data are shown as mean ± SEM.
Spcas9 2nls Nuclease, supplied by Synthego Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti-c-rel+cat/analysis+crispr+ice+tool/pm38430908-265-99-97
Average 86 stars, based on 1 article reviews
spcas9 2nls nuclease - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
protein a g agarose beads  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology protein a g agarose beads
a , b Hallmark pathway of TNFA_NFKB ( a ) and KRAS ( b ) signaling AUC score cluster distributions. c , d Violin plots of the AUC score in TNFA_NFKB ( c ) and KRAS ( d ) signaling in KCs. e – g IB analysis of the indicated proteins of NF-κB and MAPK signaling pathway in HaCaT after treatment with LZTR1 sgRNA ( e ), primary mouse KC ( f ), and mouse epidermis ( g ). h – n MFI level of membrane HLA-ABC or mRNA level of HLA-A, HLA-B in Ctrl and LZTR1 KO HaCaT treated with 5 μM NF-κB inhibitor QNZ ( h – j ), si <t>NFKB1</t> ( k , l ) or overexpressed (oe)- NFKB1 ( m , n ). veh, vehicle ( n = 2–4). o qPCR of H2-D1 and H2-K1 mRNA expression in KCs from mice treated with si Nfkb1 and IFNγ ( n = 4). p , q Schematic diagram of promoter site construction and results for dual luciferase assay of HLA-A ( p ) and HLA-B ( q ) with si NFKB1 or oe- NFKB1 ( n = 3). r Relative enrichment fold of HLA-A and HLA-B promoter sequence immunoprecipitated with NF-κB1 in HaCaT analyzed by qPCR ( n = 3). s NF-κB1 predictive binding site on HLA-A and HLA-B promoter. t Schematic diagram of NF-κB1-binding deficiency promoter construction. u – x Quantification of luciferase activity level of HLA-A and HLA-B in WT or mutant promoter combined with si NFKB1 ( u , v ) and LZTR1 KO ( w , x ) ( n = 3). y Schematic mechanism diagram of LZTR1 regulating MHC-I. ns: not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 by Wilcoxon rank test ( c ), one-way ANOVA ( k ) and two-way ANOVA ( i , j , l , n – r , u – x ). Data are shown as mean ± SEM.
Protein A G Agarose Beads, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti-c-rel+cat/Protein+A%2FG+PLUS-Agarose/pm37222520-126-22-28
Average 96 stars, based on 1 article reviews
protein a g agarose beads - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
67489s  (Cell Signaling Technology Inc)
94
Cell Signaling Technology Inc 67489s
a , b Hallmark pathway of TNFA_NFKB ( a ) and KRAS ( b ) signaling AUC score cluster distributions. c , d Violin plots of the AUC score in TNFA_NFKB ( c ) and KRAS ( d ) signaling in KCs. e – g IB analysis of the indicated proteins of NF-κB and MAPK signaling pathway in HaCaT after treatment with LZTR1 sgRNA ( e ), primary mouse KC ( f ), and mouse epidermis ( g ). h – n MFI level of membrane HLA-ABC or mRNA level of HLA-A, HLA-B in Ctrl and LZTR1 KO HaCaT treated with 5 μM NF-κB inhibitor QNZ ( h – j ), si <t>NFKB1</t> ( k , l ) or overexpressed (oe)- NFKB1 ( m , n ). veh, vehicle ( n = 2–4). o qPCR of H2-D1 and H2-K1 mRNA expression in KCs from mice treated with si Nfkb1 and IFNγ ( n = 4). p , q Schematic diagram of promoter site construction and results for dual luciferase assay of HLA-A ( p ) and HLA-B ( q ) with si NFKB1 or oe- NFKB1 ( n = 3). r Relative enrichment fold of HLA-A and HLA-B promoter sequence immunoprecipitated with NF-κB1 in HaCaT analyzed by qPCR ( n = 3). s NF-κB1 predictive binding site on HLA-A and HLA-B promoter. t Schematic diagram of NF-κB1-binding deficiency promoter construction. u – x Quantification of luciferase activity level of HLA-A and HLA-B in WT or mutant promoter combined with si NFKB1 ( u , v ) and LZTR1 KO ( w , x ) ( n = 3). y Schematic mechanism diagram of LZTR1 regulating MHC-I. ns: not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 by Wilcoxon rank test ( c ), one-way ANOVA ( k ) and two-way ANOVA ( i , j , l , n – r , u – x ). Data are shown as mean ± SEM.
67489s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti-c-rel+cat/c-Rel+Rabbit+mAb/pm38430908-265-18-32
Average 94 stars, based on 1 article reviews
67489s - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
antiptprc/cd45 antibody  (Becton Dickinson)
90
Becton Dickinson antiptprc/cd45 antibody
a , b Hallmark pathway of TNFA_NFKB ( a ) and KRAS ( b ) signaling AUC score cluster distributions. c , d Violin plots of the AUC score in TNFA_NFKB ( c ) and KRAS ( d ) signaling in KCs. e – g IB analysis of the indicated proteins of NF-κB and MAPK signaling pathway in HaCaT after treatment with LZTR1 sgRNA ( e ), primary mouse KC ( f ), and mouse epidermis ( g ). h – n MFI level of membrane HLA-ABC or mRNA level of HLA-A, HLA-B in Ctrl and LZTR1 KO HaCaT treated with 5 μM NF-κB inhibitor QNZ ( h – j ), si <t>NFKB1</t> ( k , l ) or overexpressed (oe)- NFKB1 ( m , n ). veh, vehicle ( n = 2–4). o qPCR of H2-D1 and H2-K1 mRNA expression in KCs from mice treated with si Nfkb1 and IFNγ ( n = 4). p , q Schematic diagram of promoter site construction and results for dual luciferase assay of HLA-A ( p ) and HLA-B ( q ) with si NFKB1 or oe- NFKB1 ( n = 3). r Relative enrichment fold of HLA-A and HLA-B promoter sequence immunoprecipitated with NF-κB1 in HaCaT analyzed by qPCR ( n = 3). s NF-κB1 predictive binding site on HLA-A and HLA-B promoter. t Schematic diagram of NF-κB1-binding deficiency promoter construction. u – x Quantification of luciferase activity level of HLA-A and HLA-B in WT or mutant promoter combined with si NFKB1 ( u , v ) and LZTR1 KO ( w , x ) ( n = 3). y Schematic mechanism diagram of LZTR1 regulating MHC-I. ns: not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 by Wilcoxon rank test ( c ), one-way ANOVA ( k ) and two-way ANOVA ( i , j , l , n – r , u – x ). Data are shown as mean ± SEM.
Antiptprc/Cd45 Antibody, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti-c-rel+cat/anti+cd3/10__1038_slash_nprot__2015__007-129-29-31
Average 90 stars, based on 1 article reviews
antiptprc/cd45 antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rabbit igg isotype  (Cell Signaling Technology Inc)
97
Cell Signaling Technology Inc rabbit igg isotype
a , b Hallmark pathway of TNFA_NFKB ( a ) and KRAS ( b ) signaling AUC score cluster distributions. c , d Violin plots of the AUC score in TNFA_NFKB ( c ) and KRAS ( d ) signaling in KCs. e – g IB analysis of the indicated proteins of NF-κB and MAPK signaling pathway in HaCaT after treatment with LZTR1 sgRNA ( e ), primary mouse KC ( f ), and mouse epidermis ( g ). h – n MFI level of membrane HLA-ABC or mRNA level of HLA-A, HLA-B in Ctrl and LZTR1 KO HaCaT treated with 5 μM NF-κB inhibitor QNZ ( h – j ), si <t>NFKB1</t> ( k , l ) or overexpressed (oe)- NFKB1 ( m , n ). veh, vehicle ( n = 2–4). o qPCR of H2-D1 and H2-K1 mRNA expression in KCs from mice treated with si Nfkb1 and IFNγ ( n = 4). p , q Schematic diagram of promoter site construction and results for dual luciferase assay of HLA-A ( p ) and HLA-B ( q ) with si NFKB1 or oe- NFKB1 ( n = 3). r Relative enrichment fold of HLA-A and HLA-B promoter sequence immunoprecipitated with NF-κB1 in HaCaT analyzed by qPCR ( n = 3). s NF-κB1 predictive binding site on HLA-A and HLA-B promoter. t Schematic diagram of NF-κB1-binding deficiency promoter construction. u – x Quantification of luciferase activity level of HLA-A and HLA-B in WT or mutant promoter combined with si NFKB1 ( u , v ) and LZTR1 KO ( w , x ) ( n = 3). y Schematic mechanism diagram of LZTR1 regulating MHC-I. ns: not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 by Wilcoxon rank test ( c ), one-way ANOVA ( k ) and two-way ANOVA ( i , j , l , n – r , u – x ). Data are shown as mean ± SEM.
Rabbit Igg Isotype, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti-c-rel+cat/Rabbit+mAb+IgG+XP+Isotype+Control/pm37222520-126-16-19
Average 97 stars, based on 1 article reviews
rabbit igg isotype - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
c646 selleck cat  (Selleck Chemicals)
95
Selleck Chemicals c646 selleck cat
a , b Hallmark pathway of TNFA_NFKB ( a ) and KRAS ( b ) signaling AUC score cluster distributions. c , d Violin plots of the AUC score in TNFA_NFKB ( c ) and KRAS ( d ) signaling in KCs. e – g IB analysis of the indicated proteins of NF-κB and MAPK signaling pathway in HaCaT after treatment with LZTR1 sgRNA ( e ), primary mouse KC ( f ), and mouse epidermis ( g ). h – n MFI level of membrane HLA-ABC or mRNA level of HLA-A, HLA-B in Ctrl and LZTR1 KO HaCaT treated with 5 μM NF-κB inhibitor QNZ ( h – j ), si <t>NFKB1</t> ( k , l ) or overexpressed (oe)- NFKB1 ( m , n ). veh, vehicle ( n = 2–4). o qPCR of H2-D1 and H2-K1 mRNA expression in KCs from mice treated with si Nfkb1 and IFNγ ( n = 4). p , q Schematic diagram of promoter site construction and results for dual luciferase assay of HLA-A ( p ) and HLA-B ( q ) with si NFKB1 or oe- NFKB1 ( n = 3). r Relative enrichment fold of HLA-A and HLA-B promoter sequence immunoprecipitated with NF-κB1 in HaCaT analyzed by qPCR ( n = 3). s NF-κB1 predictive binding site on HLA-A and HLA-B promoter. t Schematic diagram of NF-κB1-binding deficiency promoter construction. u – x Quantification of luciferase activity level of HLA-A and HLA-B in WT or mutant promoter combined with si NFKB1 ( u , v ) and LZTR1 KO ( w , x ) ( n = 3). y Schematic mechanism diagram of LZTR1 regulating MHC-I. ns: not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 by Wilcoxon rank test ( c ), one-way ANOVA ( k ) and two-way ANOVA ( i , j , l , n – r , u – x ). Data are shown as mean ± SEM.
C646 Selleck Cat, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti-c-rel+cat/C646/pm32460017-235-236-237
Average 95 stars, based on 1 article reviews
c646 selleck cat - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
antiphospho crkl  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc antiphospho crkl
a , b Hallmark pathway of TNFA_NFKB ( a ) and KRAS ( b ) signaling AUC score cluster distributions. c , d Violin plots of the AUC score in TNFA_NFKB ( c ) and KRAS ( d ) signaling in KCs. e – g IB analysis of the indicated proteins of NF-κB and MAPK signaling pathway in HaCaT after treatment with LZTR1 sgRNA ( e ), primary mouse KC ( f ), and mouse epidermis ( g ). h – n MFI level of membrane HLA-ABC or mRNA level of HLA-A, HLA-B in Ctrl and LZTR1 KO HaCaT treated with 5 μM NF-κB inhibitor QNZ ( h – j ), si <t>NFKB1</t> ( k , l ) or overexpressed (oe)- NFKB1 ( m , n ). veh, vehicle ( n = 2–4). o qPCR of H2-D1 and H2-K1 mRNA expression in KCs from mice treated with si Nfkb1 and IFNγ ( n = 4). p , q Schematic diagram of promoter site construction and results for dual luciferase assay of HLA-A ( p ) and HLA-B ( q ) with si NFKB1 or oe- NFKB1 ( n = 3). r Relative enrichment fold of HLA-A and HLA-B promoter sequence immunoprecipitated with NF-κB1 in HaCaT analyzed by qPCR ( n = 3). s NF-κB1 predictive binding site on HLA-A and HLA-B promoter. t Schematic diagram of NF-κB1-binding deficiency promoter construction. u – x Quantification of luciferase activity level of HLA-A and HLA-B in WT or mutant promoter combined with si NFKB1 ( u , v ) and LZTR1 KO ( w , x ) ( n = 3). y Schematic mechanism diagram of LZTR1 regulating MHC-I. ns: not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 by Wilcoxon rank test ( c ), one-way ANOVA ( k ) and two-way ANOVA ( i , j , l , n – r , u – x ). Data are shown as mean ± SEM.
Antiphospho Crkl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti-c-rel+cat/Phospho-CrkL+(Tyr207)+Antibody/10__1038_slash_nprot__2015__007-129-19-24
Average 95 stars, based on 1 article reviews
antiphospho crkl - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

Image Search Results


KEY RESOURCES TABLE

Journal: Molecular cell

Article Title: Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression

doi: 10.1016/j.molcel.2018.10.034

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Mouse monoclonal anti-c-Rel , Santa Cruz , Cat# sc-6955; RRID: AB_670194.

Techniques: Virus, Recombinant, Control, Mutagenesis, Kinase Assay, Sequencing, CRAfT Assay, Software

a , b Hallmark pathway of TNFA_NFKB ( a ) and KRAS ( b ) signaling AUC score cluster distributions. c , d Violin plots of the AUC score in TNFA_NFKB ( c ) and KRAS ( d ) signaling in KCs. e – g IB analysis of the indicated proteins of NF-κB and MAPK signaling pathway in HaCaT after treatment with LZTR1 sgRNA ( e ), primary mouse KC ( f ), and mouse epidermis ( g ). h – n MFI level of membrane HLA-ABC or mRNA level of HLA-A, HLA-B in Ctrl and LZTR1 KO HaCaT treated with 5 μM NF-κB inhibitor QNZ ( h – j ), si NFKB1 ( k , l ) or overexpressed (oe)- NFKB1 ( m , n ). veh, vehicle ( n = 2–4). o qPCR of H2-D1 and H2-K1 mRNA expression in KCs from mice treated with si Nfkb1 and IFNγ ( n = 4). p , q Schematic diagram of promoter site construction and results for dual luciferase assay of HLA-A ( p ) and HLA-B ( q ) with si NFKB1 or oe- NFKB1 ( n = 3). r Relative enrichment fold of HLA-A and HLA-B promoter sequence immunoprecipitated with NF-κB1 in HaCaT analyzed by qPCR ( n = 3). s NF-κB1 predictive binding site on HLA-A and HLA-B promoter. t Schematic diagram of NF-κB1-binding deficiency promoter construction. u – x Quantification of luciferase activity level of HLA-A and HLA-B in WT or mutant promoter combined with si NFKB1 ( u , v ) and LZTR1 KO ( w , x ) ( n = 3). y Schematic mechanism diagram of LZTR1 regulating MHC-I. ns: not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 by Wilcoxon rank test ( c ), one-way ANOVA ( k ) and two-way ANOVA ( i , j , l , n – r , u – x ). Data are shown as mean ± SEM.

Journal: Cell Discovery

Article Title: LZTR1 regulates epithelial MHC-I expression via NF-κB1 to modulate CD8 + T cells activation

doi: 10.1038/s41421-025-00837-6

Figure Lengend Snippet: a , b Hallmark pathway of TNFA_NFKB ( a ) and KRAS ( b ) signaling AUC score cluster distributions. c , d Violin plots of the AUC score in TNFA_NFKB ( c ) and KRAS ( d ) signaling in KCs. e – g IB analysis of the indicated proteins of NF-κB and MAPK signaling pathway in HaCaT after treatment with LZTR1 sgRNA ( e ), primary mouse KC ( f ), and mouse epidermis ( g ). h – n MFI level of membrane HLA-ABC or mRNA level of HLA-A, HLA-B in Ctrl and LZTR1 KO HaCaT treated with 5 μM NF-κB inhibitor QNZ ( h – j ), si NFKB1 ( k , l ) or overexpressed (oe)- NFKB1 ( m , n ). veh, vehicle ( n = 2–4). o qPCR of H2-D1 and H2-K1 mRNA expression in KCs from mice treated with si Nfkb1 and IFNγ ( n = 4). p , q Schematic diagram of promoter site construction and results for dual luciferase assay of HLA-A ( p ) and HLA-B ( q ) with si NFKB1 or oe- NFKB1 ( n = 3). r Relative enrichment fold of HLA-A and HLA-B promoter sequence immunoprecipitated with NF-κB1 in HaCaT analyzed by qPCR ( n = 3). s NF-κB1 predictive binding site on HLA-A and HLA-B promoter. t Schematic diagram of NF-κB1-binding deficiency promoter construction. u – x Quantification of luciferase activity level of HLA-A and HLA-B in WT or mutant promoter combined with si NFKB1 ( u , v ) and LZTR1 KO ( w , x ) ( n = 3). y Schematic mechanism diagram of LZTR1 regulating MHC-I. ns: not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 by Wilcoxon rank test ( c ), one-way ANOVA ( k ) and two-way ANOVA ( i , j , l , n – r , u – x ). Data are shown as mean ± SEM.

Article Snippet: Equal amounts of protein were resolved by SDS–PAGE and immunoblotted with anti-LZTR1 (cat. ab289965, Abcam, 1:1000), anti-HLA-A (cat. ab52922, Abcam, 1:1000), anti-HLA-B (cat. ab193415, Abcam, 1:1000), anti-HLA-C (cat. sc-166057, Santa Cruz, 1:100), anti-GAPDH (cat. 60004-I-Ig, Proteintech, 1:3000), anti-HLA-C (cat. PA5-79367, Thermo Fisher, 1:1000), anti-NFκB1 p105/p50 (cat. 13586S, CST, 1:1000), anti-NFκB2 p100/p52 (cat. 37359S, CST, 1:1000), anti-NFκB p65 (cat. 8242S, CST, 1:1000), anti-pho-NFκB p65 (cat. 3033S, CST, 1:1000), anti-c-REL (cat. ab133251, Abcam, 1:1000), Anti-Erk (cat. 4695S, CST, 1:1000), anti-p-Erk (cat. 4370S, CST, 1:1000), anti-P38 (cat. 8690S, CST, 1:1000), anti-p-P38 (cat. 4511S, CST, 1:1000), anti-TUBULIN (cat. 11224-1-AP, Proteintech, 1:2000), anti-FLAG (cat. F1804-1MG, Sigma, 1:1000), anti-HA-Tag (cat. sc-7392, Santa Cruz, 1:100), anti-PSMA6 (cat. ab109377, Abcam, 1:50000), anti-PAMS7 (cat. ab133502, Abcam, 1:1000), anti-RPS3 (cat. ab128995, Abcam, 1:1000), anti-Ubiquitin (cat. sc-8017, Santa Cruz, 1:100).

Techniques: Membrane, Expressing, Luciferase, Sequencing, Immunoprecipitation, Binding Assay, Activity Assay, Mutagenesis

a , b IB analysis of HaCaT treated with 400 nM Baf-A1 ( a ) and 20 μM MG132 ( b ) for the indicated times. Right: summary plot of IB. c – f Ctrl and LZTR1 KO HaCaT cells were treated with 50 μg/mL CHX ( c ) and 20 μM MG132 ( d ) for the indicated times, and corresponding NF-κB1 quantification ( e , f ). g IB analysis of FLAG-LZTR1, PSMA6, PSMA7, and RPS3 in FLAG-LZTR1 precipitates immunoprecipitated from HaCaT cells reconstituted with either empty vector (EV) or FLAG-tagged human LZTR1. WCL: whole cell lysate. h Schematic domain structure of LZTR1 and design on domain mutation. i IB analysis of FLAG-LZTR1 and HA-RPS3 in FLAG-LZTR1 precipitates immunoprecipitated from HaCaT cells transfected with EV (−), FLAG-LZTR1 (FULL), FLAG-LZTR1 ΔKelch (ΔKelch), FLAG-LZTR1 ΔBTB1 (ΔBTB1), FLAG-LZTR1 ΔBTB2 (ΔBTB2) along with HA-RPS3. j IF of proteasome alpha unit and RPS3 in LZTR1 KO HaCaT cells transfected with different plasmid by confocal microscopy. Scale bars, 5 μm. k IB analysis of NF-κB1 (p50) and HLA-C expression in LZTR1 KO HaCaT cells additionally transfected with EV (−), FLAG-LZTR1 (FULL), FLAG-LZTR1 ΔKelch (ΔKelch), FLAG-LZTR1 ΔBTB1 (ΔBTB1), FLAG-LZTR1 ΔBTB2 (ΔBTB2). l , m FCM of HLA-ABC expression in LZTR1 KO HaCaT cells additionally transfected with EV (−), FLAG-LZTR1 (FULL), FLAG-LZTR1 ΔKelch (ΔKelch), FLAG-LZTR1 ΔBTB1 (ΔBTB1), FLAG-LZTR1 ΔBTB2 (ΔBTB2) and Quantitation ( m ) ( n = 3). n qPCR of HLA-A, HLA-B mRNA expression among LZTR1 KO HaCaT cells transfected with EV (−), FLAG-LZTR1 (FULL), FLAG-LZTR1 ΔKelch (ΔKelch), FLAG-LZTR1 ΔBTB1 (ΔBTB1), FLAG-LZTR1 ΔBTB2 (ΔBTB2) ( n = 3). o Mechanistic model of LZTR1 on co-translational biogenesis process. Up: ubiquitination-dependent p50 generation from p105; down: ubiquitination-independent but LZTR1-involved p50 generation from p105. ns: not significant; ** P < 0.01, **** P < 0.0001 by one-way ANOVA ( m , n ). Data are shown as mean ± SEM.

Journal: Cell Discovery

Article Title: LZTR1 regulates epithelial MHC-I expression via NF-κB1 to modulate CD8 + T cells activation

doi: 10.1038/s41421-025-00837-6

Figure Lengend Snippet: a , b IB analysis of HaCaT treated with 400 nM Baf-A1 ( a ) and 20 μM MG132 ( b ) for the indicated times. Right: summary plot of IB. c – f Ctrl and LZTR1 KO HaCaT cells were treated with 50 μg/mL CHX ( c ) and 20 μM MG132 ( d ) for the indicated times, and corresponding NF-κB1 quantification ( e , f ). g IB analysis of FLAG-LZTR1, PSMA6, PSMA7, and RPS3 in FLAG-LZTR1 precipitates immunoprecipitated from HaCaT cells reconstituted with either empty vector (EV) or FLAG-tagged human LZTR1. WCL: whole cell lysate. h Schematic domain structure of LZTR1 and design on domain mutation. i IB analysis of FLAG-LZTR1 and HA-RPS3 in FLAG-LZTR1 precipitates immunoprecipitated from HaCaT cells transfected with EV (−), FLAG-LZTR1 (FULL), FLAG-LZTR1 ΔKelch (ΔKelch), FLAG-LZTR1 ΔBTB1 (ΔBTB1), FLAG-LZTR1 ΔBTB2 (ΔBTB2) along with HA-RPS3. j IF of proteasome alpha unit and RPS3 in LZTR1 KO HaCaT cells transfected with different plasmid by confocal microscopy. Scale bars, 5 μm. k IB analysis of NF-κB1 (p50) and HLA-C expression in LZTR1 KO HaCaT cells additionally transfected with EV (−), FLAG-LZTR1 (FULL), FLAG-LZTR1 ΔKelch (ΔKelch), FLAG-LZTR1 ΔBTB1 (ΔBTB1), FLAG-LZTR1 ΔBTB2 (ΔBTB2). l , m FCM of HLA-ABC expression in LZTR1 KO HaCaT cells additionally transfected with EV (−), FLAG-LZTR1 (FULL), FLAG-LZTR1 ΔKelch (ΔKelch), FLAG-LZTR1 ΔBTB1 (ΔBTB1), FLAG-LZTR1 ΔBTB2 (ΔBTB2) and Quantitation ( m ) ( n = 3). n qPCR of HLA-A, HLA-B mRNA expression among LZTR1 KO HaCaT cells transfected with EV (−), FLAG-LZTR1 (FULL), FLAG-LZTR1 ΔKelch (ΔKelch), FLAG-LZTR1 ΔBTB1 (ΔBTB1), FLAG-LZTR1 ΔBTB2 (ΔBTB2) ( n = 3). o Mechanistic model of LZTR1 on co-translational biogenesis process. Up: ubiquitination-dependent p50 generation from p105; down: ubiquitination-independent but LZTR1-involved p50 generation from p105. ns: not significant; ** P < 0.01, **** P < 0.0001 by one-way ANOVA ( m , n ). Data are shown as mean ± SEM.

Article Snippet: Equal amounts of protein were resolved by SDS–PAGE and immunoblotted with anti-LZTR1 (cat. ab289965, Abcam, 1:1000), anti-HLA-A (cat. ab52922, Abcam, 1:1000), anti-HLA-B (cat. ab193415, Abcam, 1:1000), anti-HLA-C (cat. sc-166057, Santa Cruz, 1:100), anti-GAPDH (cat. 60004-I-Ig, Proteintech, 1:3000), anti-HLA-C (cat. PA5-79367, Thermo Fisher, 1:1000), anti-NFκB1 p105/p50 (cat. 13586S, CST, 1:1000), anti-NFκB2 p100/p52 (cat. 37359S, CST, 1:1000), anti-NFκB p65 (cat. 8242S, CST, 1:1000), anti-pho-NFκB p65 (cat. 3033S, CST, 1:1000), anti-c-REL (cat. ab133251, Abcam, 1:1000), Anti-Erk (cat. 4695S, CST, 1:1000), anti-p-Erk (cat. 4370S, CST, 1:1000), anti-P38 (cat. 8690S, CST, 1:1000), anti-p-P38 (cat. 4511S, CST, 1:1000), anti-TUBULIN (cat. 11224-1-AP, Proteintech, 1:2000), anti-FLAG (cat. F1804-1MG, Sigma, 1:1000), anti-HA-Tag (cat. sc-7392, Santa Cruz, 1:100), anti-PSMA6 (cat. ab109377, Abcam, 1:50000), anti-PAMS7 (cat. ab133502, Abcam, 1:1000), anti-RPS3 (cat. ab128995, Abcam, 1:1000), anti-Ubiquitin (cat. sc-8017, Santa Cruz, 1:100).

Techniques: Immunoprecipitation, Plasmid Preparation, Mutagenesis, Transfection, Confocal Microscopy, Expressing, Quantitation Assay, Ubiquitin Proteomics